Alterity Therapeutics (ASX:ATH) has announced that new data related to ATH434 was presented at the Society for Neuroscience in the US.
The poster, ‘Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuclein Aggregation with Moderate Iron-binding Affinity’, presents new data indicating that ATH434 can preserve mitochondrial function after oxidative injury and exert direct anti-oxidant activity independent of its iron binding properties.
The company said these features were not observed with another iron-binding agent approved for treating iron overload, which was also investigated.
The study was run under the direction of Dr Daniel J. Kosman, Distinguished Professor of Biochemistry at the State University of New York at Buffalo.
Alterity CEO Dr David Stamler said, “These exciting new data underscore the potential of ATH434 as a treatment for neurodegenerative diseases, including Parkinson’s disease and related disorders. We have long known that ATH434 is able to reduce labile iron which, when elevated, can drive oxidative stress.
“The demonstrated mitochondrial protection may reveal additional mechanisms that augment its ability to slow disease progression. We are grateful for the valued contributions from our collaborators in Dr. Kosman’s laboratory at SUNY-Buffalo.”
